Investor Relations Home
Portola Pharmaceuticals was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering (IPO) in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 70 employees.More >>
|10/16/14||Portola Pharmaceuticals Announces Commercial Supply Agreement for Andexanet Alfa With Lonza|
|SOUTH SAN FRANCISCO, Calif., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has executed a supply agreement with Lonza for the commercial manufacturing of andexanet alfa. An FDA-designated breakthrough therapy, andexanet alfa is the only recombinant Factor Xa molecule designed to specifically reverse the effects of oral and injectable Factor Xa inhibitors. It is being developed as an antidote for patients receiving one of these anticoagulants who ... |
|10/02/14||Portola Announces Pricing of Public Offering of Common Stock|
|SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today the pricing of its underwritten public offering of 6,200,000 shares of its common stock at a price to the public of $26.00 per share. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 930,000 shares from Portola at the public offering price. The offering is expected to close on October 8, 2014, subject to customary... |
|10/01/14||Portola Pharmaceuticals Announces Proposed Offering of Common Stock|
|SOUTH SAN FRANCISCO, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000. All of the shares of common stock in the offering will be sold by Portola Pharmaceuticals. Subject to market and other conditions, the offering is expected to price before 9:30 a.m., EDT, on October 3, 2014.
Morgan Stanley and... |
|10/01/14||Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance|
|Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special Reports" Session on November 17
SOUTH SAN FRANCISCO, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough ... |
|09/02/14||Portola Pharmaceuticals to Present at the 2014 Morgan Stanley Global Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the 2014 Morgan Stanley Global Healthcare Conference on Tuesday, September 9, at 2:55 p.m. Eastern Time in New York City.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharm... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.